Leap Therapeutics Inc
NASDAQ:LPTX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Leap Therapeutics Inc
NASDAQ:LPTX
|
US |
|
A
|
Andlauer Healthcare Group Inc
TSX:AND
|
CA |
|
T
|
Titijaya Land Bhd
KLSE:TITIJYA
|
MY |
|
D
|
Dof Robotik Sanayi AS
IST:DOFRB.E
|
TR |
|
Bharat Rasayan Ltd
NSE:BHARATRAS
|
IN |
|
Kalpataru Power Transmission Ltd
NSE:KALPATPOWR
|
IN |
|
M
|
Motor & General Finance Ltd
NSE:MOTOGENFIN
|
IN |
Leap Therapeutics Inc
Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 36 full-time employees. The company went IPO on 2017-01-24. The firm is focused on developing therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways and by harnessing the immune system to attack cancer cells. The Company’s clinical stage program is DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1 (DKK1). DKK1 is a protein that regulates the Wnt signaling pathways and enables tumor cells to proliferate and spread, as well as suppresses the immune system from attacking the tumor. When DKN-01 binds to DKK1, an anti-tumor effect can be generated. DKK1 is a cell secreted protein that research has found its role in embryonic development. DKN-01 is an affinity, neutralizing monoclonal antibody targeting DKK1. DKN-01 reduces free DKK1 levels and has demonstrated an anti-tumor effect in preclinical models.
Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 36 full-time employees. The company went IPO on 2017-01-24. The firm is focused on developing therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways and by harnessing the immune system to attack cancer cells. The Company’s clinical stage program is DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1 (DKK1). DKK1 is a protein that regulates the Wnt signaling pathways and enables tumor cells to proliferate and spread, as well as suppresses the immune system from attacking the tumor. When DKN-01 binds to DKK1, an anti-tumor effect can be generated. DKK1 is a cell secreted protein that research has found its role in embryonic development. DKN-01 is an affinity, neutralizing monoclonal antibody targeting DKK1. DKN-01 reduces free DKK1 levels and has demonstrated an anti-tumor effect in preclinical models.
